MANAGEMENT
COSIMO SANTELLA
BTech
Lead Product Engineer
Cosimo completed his tertiary education at Edith Cowan University Western Australia. He began his career in high precision robotics developing electronic motion control systems before heading overseas. Cos now has over 20 years of product experience, having spent the majority of his time based in Cambridge, United Kingdom. Cos has worked with world leading automotive brands, medical technology companies, fast-moving goods manufacturers and industrial technologies. Cos returned to Perth and joined OncoRes Medical in mid- 2020.
SOFIE DE WOLF
ACCA, MA, MBS
Chief Financial Officer
Sofie is a qualified accountant with international experience in investment fund accounting and fund reporting. Originally from Belgium, Sofie started her financial career in Dublin (Ireland) where she worked for Citco Fund Services and AIB/BNY Fund Management as a fund accountant and fund reporting supervisor, responsible for the accounting and reporting function of various types of funds. Sofie is the Financial Controller at Stone Ridge Ventures, responsible for the financial operations and reporting of the management company, the SRV Trusts and various portfolio companies. Sofie also assumes the role of Company Secretary for these entities. Sofie is a member of the Association of Chartered Certified Accountants (ACCA). She received the silver medal for achieving the 2nd highest mark worldwide in her final accounting exams. In 2009 she was awarded the WA Dux prize for Applied Corporate Law by Chartered Secretaries Australia (CSA).
DR KATHARINE GILES
MBBS, MBA, GAICD
CEO/Managing Director
Kath joined Brandon Capital Partners in 2012. Prior to this Kath was an Investment Manager with Perth based Stone Ridge Ventures, a fund manager specialising in seed-to-early stage technology investment. In addition to her investment experience Kath has start up experience in medical apps, diagnostics and fitness devices. Kath still practices as a medical doctor mainly working within the surgical field and has experience as a medical officer monitoring clinical trials. Before entering the commercial world Kath spent a few years working in clinical medicine gaining a range of experience across medical and surgical specialities and critical care. Kath is a Director of the Curtin Commercialisation Advisory Board. Kath graduated from her medical degree (MBBS) with Honours and has an MBA from the University of Western Australia. Kath is also a Graduate of the Australian Institute of Company Directors.
MR ALEX CAMPOS
B Eng, M Eng
Vice President of R&D
An agile product strategist and realisation specialist with broad engineering expertise and proven commercial and management skills. Demonstrably successful in the leadership and mentoring of cross-functional teams working on proof-of-concept research, design and development, regulatory approvals, manufacturing, and market launch phases of new product development. Equally successful in meeting commercial demands, from raising capital to the engagement of commercialisation channels, authoring market aware product roadmaps and marketing collateral.
Having performed executive roles such as Director Design & Development, VP Engineering, Market Development Manager and Engineering Manager and blending such roles with board level directorships culminate in a valuable combination of extensive technical, operational, and commercial experience.
DR SIMON GRAINDORGE
PhD, B Eng (Hons), BSc, CEng
Chief Operating Officer
Simon is also an Operating Partner with IP Group Australia, and has spent almost 20 years as an investor and operator in medical device and digital health companies in the UK. He has extensive experience as both an operating executive and board director investing in, building and growing start-ups, early stage and emerging growth companies based on early-stage, deep technology innovations across healthcare. Before joining IP Group Australia as an Operating Partner, Simon was a Partner in the UK life sciences team at IP Group plc, leading investment strategy and portfolio in medtech and digital health/healthtech. Over the last decade he has invested in and helped build companies like Tissue Regenix Group plc, Oxehealth, Creavo Medical Technologies, Intelligent Ultrasound Group plc, Ibex Innovations, Pancregenesis. Simon joined IP Group from Ceramex Ltd, a corporate spin-out of the Hexadex Group and was previously an Executive Director at Tissue Regenix Group plc. Simon holds a PhD in Biomedical Engineering from the University of Western Australia, and Bachelor degrees in both Mechanical Engineering and Chemistry, and is also a Chartered Engineer.
PROF CHRISTOBEL SAUNDERS AO
MB, BSc, FRCS, FAAHMS
Chief Medical Officer
Christobel was 2018 WA Women’s Hall of Fame Inductee International Women’s Day, 2017 WA Scientist of the Year and is internationally recognised as one of Australia’s most prominent research-orientated cancer surgeons. She has substantially contributed to many clinical aspects of breast cancer research including clinical trials of new treatments, psychosocial, translational and health services research and is active in several areas of surgical oncology cancer research, with a particular emphasis on breast cancer. She has performed research for 20+ years evaluating the efficacy and utility of therapy for early breast cancer. Her career started as a surgical trainee in the UK and then Consultant Surgeon and Senior Lecturer at University College Hospitals in London, before moving to Australia in 2000 as a surgeon at Royal Perth Hospital and since 2002 as Professor of Surgical Oncology at the University of Western Australia and holds both clinical and research roles in the breast and melanoma cancer field.
BOARD OF DIRECTORS
DR KATHARINE GILES
MBBS, MBA, GAICD
CEO/Managing Director
Kath joined Brandon Capital Partners in 2012. Prior to this Kath was an Investment Manager with Perth-based Stone Ridge Ventures, a fund manager specialising in seed-to-early stage technology investment. In addition to her investment experience Kath has startup experience in medical apps, diagnostics and fitness devices. Kath still practices as a medical doctor mainly working within the surgical field and has experience as a medical officer monitoring clinical trials. Before entering the commercial world Kath spent a few years working in clinical medicine gaining a range of experience across medical and surgical specialities and critical care. Kath is a Director of the Curtin Commercialisation Advisory Board. Kath graduated from her medical degree (MBBS) with Honours and has an MBA from the University of Western Australia. Kath is also a Graduate of the Australian Institute of Company Directors.
DR STEPHEN THOMPSON
PhD, MBA, GAICD
Chairman
Stephen is a founding partner of Brandon Capital Partners. Prior to this Stephen was a Director of Apax Partners based in London. Previously he fulfilled roles in product development with UK biotechnology company Cantab Pharmaceuticals. Earlier, Stephen spent ten years as a research immunologist in London and California. Stephen has an Honours degree in Immunology and Biochemistry, a PhD in Immunology from Kings College London and an MBA from Imperial College London. Stephen is a Director of; MecRx P/L, Vaxxas P/L, a former Director of Elastagen P/L acquired by Allergan Inc and a Director of the Australian Venture Capital Association Limited (AVCAL). Stephen is a graduate of the Australian Institute of Company Directors.
STEWART BARTLETT
MBA, BEng(Hons)
Non-Executive Director
Stewart is the CEO of medical device company Ferronova and co-founder of smart ultrasound company Signostics. From 2005-2017 he was COO of Signostics, managing product development, manufacturing, quality, regulatory, customer service, OEM partnerships, and at various times sales and marketing. Prior to Signostics, he held several management positions at Lake Technology Ltd, including managing director of a subsidiary responsible for licensing Lake’s technology. Stewart has worked in a variety of management, engineering and sales and marketing roles in Australia, the United States, and Europe, and holds a Bachelor of Electrical Engineering with Honors from Curtin University and a Master of Business Administration from The Australian Graduate School of Management.
JILL ANDERSON
BA Fin, MBA
Non-Executive Director
Jill is dedicated to enhancing the lives of consumers through medical technology. Recognized for her role in stimulating innovative and creative market-driven solutions, she focuses on strategy and execution, leveraging expert talent, engaging others in a vision, and taking evaluated risks. Jill is a business strategist and commercial expert with extensive industry experience in medical devices and healthcare services. She was co-founder, President and Chief Executive Officer of Cianna Medical from 2008 until its acquisition in 2018. Prior to that, she was Vice President of BioLucent from 2001 to 2003, becoming President in 2003 until its acquisition in 2007. Prior to entering the medical device field, Jill held executive leadership positions in health care services, focused on developing patient-centric, comprehensive cancer centers in partnership with large, teaching hospital environments. In addition to her service on the OncoRes Board, Jill also serves on the Board of Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy.
Jill holds a Bachelor of Arts degree in Finance and an M.B.A from Temple University in Philadelphia, PA
SCIENTIFIC
ADVISORY BOARD
DR EMAN NAMATI
PhD, BEng, BSc
Advisor
Eman is currently the CEO at SpectraWAVE. Previously he was the President and CEO of NinePoint Medical, a medical device company pioneering the use of Optical Coherence Tomography (OCT) for gastrointestinal applications. Eman joined NinePoint during its inception in 2010 as a technical co-founder and most recently served as the Vice President of Research and Development. He has succesfully overseen the development of highly complex imaging systems and single-use devices from concept through commercialization. Prior to joining NinePoint, Eman was a post-doctoral research fellow at Massachusetts General Hospital and Harvard Medical School working with Professors Guillermo Tearney, MD, PhD, and Brett Bouma, PhD. He has authored and co-authored over 50 scientific publications, abstracts and book chapters in the fields of signal processing, computed tomography, multi-modal imaging and biomedical optics. Dr. Namati holds a PhD in Biomedical Engineering and a double undergraduate degree in Engineering (BEng) and Science (BSc) from Flinders University, Australia.
PROF CHRISTOBEL SAUNDERS AO
MB, BSc, FRCS, FAAHMS
Advisor
Christobel was 2018 WA Women’s Hall of Fame Inductee International Women’s Day, 2017 WA Scientist of the Year and is internationally recognised as one of Australia’s most prominent research-orientated cancer surgeons. She has substantially contributed to many clinical aspects of breast cancer research including clinical trials of new treatments, psychosocial, translational and health services research and is active in several areas of surgical oncology cancer research, with a particular emphasis on breast cancer. She has performed research for 20+ years evaluating the efficacy and utility of therapy for early breast cancer. Her career started as a surgical trainee in the UK and then Consultant Surgeon and Senior Lecturer at University College Hospitals in London, before moving to Australia in 2000 as a surgeon at Royal Perth Hospital and since 2002 as Professor of Surgical Oncology at the University of Western Australia and holds both clinical and research roles in the breast and melanoma cancer field.
DR BRUCE LATHAM
BMedSci, MBBS, FRCPA
Advisor
Bruce is a graduate of the University of Western Australia. He carried out his Anatomical Pathology training predominantly at Royal Perth Hospital and was admitted to Fellowship in 1995. Bruce has worked as an Anatomical Pathologist in both the public and private sector, and is currently an Anatomical Pathologist with PathWest at Fiona Stanley Hospital where he has a diagnostic and research interest in breast and pulmonary pathology. He is the former Chair of the RCPAQAP Anatomical Pathology General Module Committee and is an Adjunct Associate Professor at Notre Dame University. He was previously the RCPA State Councillor for Western Australia and a member of the Anatomical Pathology Advisory Committee. He served as Vice President of the College from 2015-2017. Brue was elected in November 2017 as President of The Royal College of Pathologists of Australasia for a 2 year term.
LESLIE WISE
MSc, BA, Cert.
Market Access Advisor
Leslie has over 20 years’ experience working in US reimbursement, life sciences, and MedTech fields. She is currently the Principal of EvidenceMatters, a Global Market Access consultancy. Prior to starting the company, Leslie was Vice President of Global Healthcare Economics and Healthcare Policy for Angio Dynamics. She has also worked in senior roles for Biomet and Bristol-Myers Squibb. Her expertise lies in Market Access, HTAs, Payor Relations, Strategic leadership, and reimbursement with experience in the commercialisation strategy of medical devices, orthopaedics, biologics, cell therapies, blood products and regenerative medicine. Leslie is providing OncoRes Medical with invaluable insight into the reimbursement and tendering processes in the US.